CN116870263B - Cornea bandage mirror with bionic layer structure and preparation method thereof - Google Patents
Cornea bandage mirror with bionic layer structure and preparation method thereof Download PDFInfo
- Publication number
- CN116870263B CN116870263B CN202311151277.XA CN202311151277A CN116870263B CN 116870263 B CN116870263 B CN 116870263B CN 202311151277 A CN202311151277 A CN 202311151277A CN 116870263 B CN116870263 B CN 116870263B
- Authority
- CN
- China
- Prior art keywords
- cornea
- mirror
- bandage mirror
- cornea bandage
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004087 cornea Anatomy 0.000 title claims abstract description 220
- 239000011664 nicotinic acid Substances 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 87
- -1 polyphenol compound Chemical class 0.000 claims abstract description 46
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 37
- 239000008367 deionised water Substances 0.000 claims abstract description 36
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 36
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 17
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 14
- 229920000768 polyamine Chemical group 0.000 claims abstract description 13
- 238000005406 washing Methods 0.000 claims abstract description 13
- 150000001875 compounds Chemical class 0.000 claims abstract description 8
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 70
- 239000007864 aqueous solution Substances 0.000 claims description 69
- 238000002791 soaking Methods 0.000 claims description 63
- 239000002904 solvent Substances 0.000 claims description 40
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 36
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 claims description 32
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 26
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 20
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 20
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 claims description 20
- 229960003638 dopamine Drugs 0.000 claims description 18
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 claims description 17
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 claims description 17
- 229960003321 baicalin Drugs 0.000 claims description 17
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 claims description 17
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 claims description 14
- 235000004515 gallic acid Nutrition 0.000 claims description 13
- 229940074391 gallic acid Drugs 0.000 claims description 13
- 239000004332 silver Substances 0.000 claims description 12
- 229910052709 silver Inorganic materials 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 10
- 229910001961 silver nitrate Inorganic materials 0.000 claims description 10
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 8
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 claims description 6
- 239000001263 FEMA 3042 Substances 0.000 claims description 6
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims description 6
- 241001122767 Theaceae Species 0.000 claims description 6
- 235000015523 tannic acid Nutrition 0.000 claims description 6
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 claims description 6
- 229940033123 tannic acid Drugs 0.000 claims description 6
- 229920002258 tannic acid Polymers 0.000 claims description 6
- 239000004698 Polyethylene Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229920000573 polyethylene Polymers 0.000 claims description 4
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 claims description 3
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 claims description 3
- 235000010208 anthocyanin Nutrition 0.000 claims description 3
- 239000004410 anthocyanin Substances 0.000 claims description 3
- 229930002877 anthocyanin Natural products 0.000 claims description 3
- 150000004636 anthocyanins Chemical class 0.000 claims description 3
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 claims description 3
- 235000012734 epicatechin Nutrition 0.000 claims description 3
- 230000003592 biomimetic effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 7
- 206010023332 keratitis Diseases 0.000 abstract description 7
- 230000000813 microbial effect Effects 0.000 abstract description 3
- 208000030533 eye disease Diseases 0.000 abstract 1
- 238000004140 cleaning Methods 0.000 description 26
- 230000004048 modification Effects 0.000 description 22
- 238000012986 modification Methods 0.000 description 22
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 14
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 241000191967 Staphylococcus aureus Species 0.000 description 9
- 210000001508 eye Anatomy 0.000 description 9
- 210000002540 macrophage Anatomy 0.000 description 9
- 210000002919 epithelial cell Anatomy 0.000 description 8
- 230000001678 irradiating effect Effects 0.000 description 8
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000002073 fluorescence micrograph Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 229920002306 Glycocalyx Polymers 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000004517 glycocalyx Anatomy 0.000 description 5
- 229960002773 hyaluronidase Drugs 0.000 description 5
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 4
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 4
- 108010003272 Hyaluronate lyase Proteins 0.000 description 4
- 102000001974 Hyaluronidases Human genes 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 4
- 235000012431 wafers Nutrition 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 238000006845 Michael addition reaction Methods 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 206010064996 Ulcerative keratitis Diseases 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 150000005206 1,2-dihydroxybenzenes Chemical class 0.000 description 1
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical class NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000223218 Fusarium Species 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000010065 bacterial adhesion Effects 0.000 description 1
- 238000001266 bandaging Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 208000011323 eye infectious disease Diseases 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000008798 inflammatory stress Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 206010023365 keratopathy Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000004347 surface barrier Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/082—Inorganic materials
- A61L31/088—Other specific inorganic materials not covered by A61L31/084 or A61L31/086
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/18—Modification of implant surfaces in order to improve biocompatibility, cell growth, fixation of biomolecules, e.g. plasma treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a cornea bandage mirror with a bionic layer structure and a preparation method thereof, belonging to the technical field of cornea bandage mirrors, wherein the preparation method comprises the following steps: immersing cornea bandage mirror in water solution A containing polyphenol compound, water solution B containing silver ion, water solution C containing polyphenol compound and polyamine group compound, water solution D containing polyphenol compound and water solution E containing sulfhydryl hyaluronic acid in turn, and finally washing with deionized water to obtain the cornea bandage mirror; wherein, the cornea bandage mirror is soaked in the solution B and the solution E and simultaneously irradiated by ultraviolet light. The surface of the cornea bandage mirror prepared by the method forms a bionic layer structure, so that the problem that the existing cornea bandage mirror is easy to cause microbial keratitis can be solved, the using effect of the cornea bandage mirror is greatly improved, and the purpose of preventing and treating eye diseases is improved.
Description
Technical Field
The invention relates to the technical field of cornea bandage mirrors, in particular to a cornea bandage mirror with a bionic layer structure and a preparation method thereof.
Background
The human eyes are easily affected by various external adverse factors. Such as an impaired ocular surface barrier, is susceptible to infection by pathogenic microorganisms. Keratitis is one of the most common ocular disorders, such as early treatment failure, which can further exacerbate the corneal ulceration and even perforation, ultimately leading to corneal blindness. 85% of corneal blindness is due to infectious keratopathy. Infectious keratitis is mainly caused by pathogenic microorganisms such as bacteria (e.g., staphylococcus aureus, pseudomonas aeruginosa) or fungi (e.g., aspergillus fumigatus, fusarium). The disease is urgent, the disease is serious, if the correct treatment is not carried out in time, serious complications such as corneal ulcer, perforation, eye content removal, endophthalmitis and the like can be caused, the infection can be controlled only by cornea transplantation, but the cornea donation is limited, and many patients can finally carry out eyeball excision only.
The cornea bandage mirror can be used as a bandage and a medicine warehouse to help treat intractable cornea defect and cornea wound after repair operation and provide required medicine, so that the medicine is released continuously, the residence time of the medicine on the ocular surface is greatly prolonged, the ocular bioavailability of the medicine is improved from 1% -5% of eye drops to 50%, and better curative effect and less side effect are generated. However, conventional keratobandaged lenses often cause various types of microbial keratitis during wear, and are still considered contraindicated in infectious keratitis. Therefore, how to surface modify traditional cornea bandages, develop cornea bandages with effective antibacterial performance, and establish an effective drug delivery system, which is helpful for wide use of cornea bandages and more effective prevention and control of eye infection.
Disclosure of Invention
In order to solve the defects in the prior art, the invention aims to provide a cornea bandage mirror with a bionic layer structure and a preparation method thereof, so as to solve the problem that microbial keratitis is easy to cause in the use process of the traditional cornea bandage mirror and improve the prevention effect and the treatment effect of the cornea bandage mirror.
The technical scheme for solving the technical problems is as follows:
a preparation method of a cornea bandage mirror with a bionic layer structure comprises the following steps:
immersing cornea bandage mirror in water solution A containing polyphenol compound, water solution B containing silver ion, water solution C containing polyphenol compound and polyamine group compound, water solution D containing polyphenol compound and cross-linking agent and water solution E containing sulfhydrylation hyaluronic acid in turn, and finally washing with deionized water to obtain the cornea bandage mirror;
wherein, the cornea bandage mirror is soaked in the solution B and the solution E and simultaneously irradiated by ultraviolet light.
Further, the polyphenol compound in the aqueous solution a includes at least one of dopamine, tea polyphenol, tannic acid, anthocyanin, catechol, gallic acid and epicatechin, and the mass concentration of the polyphenol compound in the aqueous solution a is 0.5-4%.
Further, the pH value of the aqueous solution A is 7.0-9.0, the soaking temperature of the cornea bandage mirror in the aqueous solution A is 20-40 ℃, and the soaking time is 1-8h.
Further, silver ions are provided by silver nitrate, the mass concentration of the silver ions in the aqueous solution B is 0.5-4%, the soaking temperature of the cornea bandage mirror in the aqueous solution B is 20-40 ℃, and the soaking time is 1-30min.
Further, the polyphenol compound in the aqueous solution C comprises at least one of dopamine, tea polyphenol, tannic acid, anthocyanin, catechol, gallic acid and epicatechin; the polyamine group compound includes at least one of hexamethylenediamine and polyethylene polyamine; the mass concentration of the polyphenol compound in the aqueous solution C is 0.5-2%, and the mass concentration of the polyamine group compound in the aqueous solution C is 0.5-5%.
Further, the soaking temperature of the cornea bandage mirror in the aqueous solution C is 25-40 ℃ and the soaking time is 12-48h.
Further, the solvent of the solution D is a mixture of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide, N-hydroxysuccinimide and water, wherein the mass fraction of the 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide in the solvent is 70-73%, the mass fraction of the N-hydroxysuccinimide in the solvent is 22-25%, and the mass fraction of the water in the solvent is 2-8%;
the mass concentration of the polyphenol compound in the solution D is 1-10%, and the polyphenol compound is at least one of gallic acid and baicalin.
Further, the soaking temperature of the cornea bandage mirror in the solution D is 25-40 ℃ and the soaking time is 0.5-2h.
Further, the mass concentration of the sulfhydryl hyaluronic acid in the aqueous solution E is 1-5%, the soaking temperature of the cornea bandage mirror in the aqueous solution E is 25-40 ℃, and the soaking time is 0.1-2h.
A cornea bandage mirror with a bionic layer structure is prepared by adopting the method.
The invention has the following beneficial effects:
when the cornea bandage mirror is soaked in the aqueous solution A, the polyphenol compound is fixed on the cornea bandage mirror through the action modes of hydrogen bond, van der Waals force, coordination bond, pi-pi accumulation and the like, so that an active site is provided for subsequent materials; when the film is soaked in the aqueous solution B, the phenolic hydroxyl groups on the polyphenol compound fixed on the surface of the cornea bandage mirror and silver ions are subjected to complexation, so that the purpose of fixing the silver ions on the surface of the polyphenol compound is realized; when the coating is soaked in the aqueous solution C, the polyphenol compound and the polyamine group compound form covalent bonds through Michael addition reaction of oxidized derivative quinone of catechol on the polyphenol compound, and more amino groups are introduced to the coating of the cornea bandage mirror; when the hydrophilic adhesive is soaked in the aqueous solution D, the polyphenol compound is grafted onto polyamine through covalent bonds formed by the reaction of amino groups and carboxyl amides, the fixation of the polyphenol compound is further realized, when the hydrophilic adhesive is soaked in the aqueous solution E, the thiol-modified hyaluronic acid is fixed on the polyphenol compound through Michael addition reaction of thiol groups and catechol derivative quinone on the polyphenol, and after the operation, a bionic ocular surface glycocalyx structure is formed on the surface of the cornea bandage mirror. The ocular surface glycocalyx is an epithelial cell epitaxial barrier formed by mucin, and plays a plurality of roles of resisting pollution and invasion of microorganisms, maintaining stable ocular surface tear layer, keeping lubrication, preserving antibacterial biomolecules, regulating and controlling ocular surface microenvironment steady state and the like. The occurrence of keratitis is often accompanied by the destruction of the eye surface glycocalyx, and the bionic eye surface glycocalyx structure formed on the surface of the cornea bandage mirror can play roles in promoting the moisture retention of eyes, promoting the repair of cornea epithelium, preventing infection and enhancing anti-pollution, thereby prolonging the wearing time of the cornea bandage mirror and realizing targeted regulation of the change of pathological microenvironment caused by the eye surface inflammation and oxidative stress.
Drawings
FIG. 1 is a schematic illustration of the preparation flow of a keratology procedure in example 1;
FIG. 2 is a graph showing the results of water contact angles before and after modification of a keratoscope;
FIG. 3 is a graph of silver ion release from a modified keratoscope;
FIG. 4 is a graph of oxidation resistance results of a modified keratology;
FIG. 5 is a fluorescence micrograph of Staphylococcus aureus and Pseudomonas aeruginosa adhesion on the surface of the corneal bandage mirror prior to modification;
FIG. 6 is a high-magnification fluorescence micrograph of modified corneal bandaging lens staphylococcus aureus and pseudomonas aeruginosa adhesion;
FIG. 7 is a fluorescence micrograph of macrophage adhesion on the surface of a corneal bandage mirror prior to modification;
FIG. 8 is a fluorescence micrograph of macrophage adhesion on the surface of the modified cornea bandages;
FIG. 9 is a fluorescence microscope image of macrophage adhesion after hyaluronidase action before and after corneal bandage mirror modification;
FIG. 10 is a fluorescence micrograph of epithelial cell adhesion on the surface of the corneal bandages before and after modification.
Detailed Description
The examples given below are only intended to illustrate the invention and are not intended to limit the scope thereof. The specific conditions are not noted in the examples and are carried out according to conventional conditions or conditions recommended by the manufacturer. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention.
Example 1
The preparation method of the cornea bandage mirror with the bionic layer structure comprises the following steps:
(1) Placing the cornea bandage mirror into 2wt% dopamine aqueous solution with pH value of 8.5, and soaking for 4h at 30deg.C;
(2) Taking out the cornea bandage mirror treated in the step (1), putting the cornea bandage mirror into a silver nitrate aqueous solution with the mass concentration of 2wt%, and soaking the cornea bandage mirror for 1min under the ultraviolet irradiation condition of 25 ℃ and 365 nm;
(3) Taking out the cornea bandage mirror treated in the step (2), cleaning with deionized water, then putting into an aqueous solution containing dopamine and hexamethylenediamine, and soaking for 24 hours at 25 ℃; the mass concentration of dopamine in the aqueous solution is 1wt%, and the mass concentration of hexamethylenediamine is 2.5wt%;
(4) Taking out the cornea bandage mirror treated in the step (3), washing with deionized water, then putting the cornea bandage mirror into a solution containing baicalin, soaking the cornea bandage mirror in the solution for 1h at the temperature of 30 ℃, wherein the solvent in the solution is a mixture of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide, N-hydroxysuccinimide and water, the mass fraction of the 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide in the solvent is 71%, the mass fraction of the N-hydroxysuccinimide in the solvent is 24%, and the mass fraction of the water in the solvent is 5%; the mass concentration of baicalin in the solution is 2wt%;
(5) Taking out the cornea bandage mirror treated in the step (4), cleaning with deionized water, then placing the cornea bandage mirror in a thiolated hyaluronic acid aqueous solution with the mass concentration of 2wt%, soaking the cornea bandage mirror for 0.5h at the temperature of 25 ℃ and then irradiating the cornea bandage mirror with ultraviolet light for 0.1h, and then cleaning the cornea bandage mirror with deionized water to obtain the cornea bandage mirror with the bionic layer structure.
Example 2
The preparation method of the cornea bandage mirror with the bionic layer structure comprises the following steps:
(1) Placing cornea bandage mirror into tannic acid water solution with mass concentration of 2wt%, wherein pH value of water solution is 8.5, and soaking for 4h at 30deg.C;
(2) Taking out the cornea bandage mirror treated in the step (1), putting the cornea bandage mirror into a silver nitrate aqueous solution with the mass concentration of 2wt%, and soaking the cornea bandage mirror for 1min under the ultraviolet irradiation condition of 25 ℃ and 365 nm;
(3) Taking out the cornea bandage mirror treated in the step (2), cleaning with deionized water, then putting into an aqueous solution containing dopamine and polyethylene polyamine, and soaking for 24 hours at 25 ℃; the mass concentration of dopamine in the aqueous solution is 1wt%, and the mass concentration of hexamethylenediamine is 2.5wt%;
(4) Taking out the cornea bandage mirror treated in the step (3), washing with deionized water, then placing the cornea bandage mirror into a solution containing gallic acid, and soaking for 1h at the temperature of 30 ℃, wherein the solvent in the solution is a mixture of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide, N-hydroxysuccinimide and water, the mass fraction of the 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide in the solvent is 71%, the mass fraction of the N-hydroxysuccinimide in the solvent is 24%, and the mass fraction of the water in the solvent is 5%; the mass concentration of gallic acid in the solution is 4wt%;
(5) Taking out the cornea bandage mirror treated in the step (4), cleaning with deionized water, then placing the cornea bandage mirror in a thiolated hyaluronic acid aqueous solution with the mass concentration of 4wt%, soaking the cornea bandage mirror for 0.5h at the temperature of 25 ℃ and then irradiating the cornea bandage mirror with ultraviolet light for 0.1h, and then cleaning the cornea bandage mirror with deionized water to obtain the cornea bandage mirror with the bionic layer structure.
Example 3
The preparation method of the cornea bandage mirror with the bionic layer structure comprises the following steps:
(1) Placing the cornea bandage mirror into a dopamine aqueous solution with the mass concentration of 1wt%, wherein the pH value of the aqueous solution is 7, and soaking for 8 hours at the temperature of 30 ℃;
(2) Taking out the cornea bandage mirror treated in the step (1), putting the cornea bandage mirror into a silver nitrate aqueous solution with the mass concentration of 2wt%, and soaking the cornea bandage mirror for 5min under the ultraviolet irradiation condition of 25 ℃ and 365 nm;
(3) Taking out the cornea bandage mirror treated in the step (2), cleaning with deionized water, then putting into an aqueous solution containing tannic acid and hexamethylenediamine, and soaking for 24 hours at 25 ℃; the mass concentration of dopamine in the aqueous solution is 1wt%, and the mass concentration of hexamethylenediamine is 2.5wt%;
(4) Taking out the cornea bandage mirror treated in the step (3), washing with deionized water, then putting the cornea bandage mirror into a solution containing baicalin, soaking the cornea bandage mirror in the solution for 1h at the temperature of 30 ℃, wherein the solvent in the solution is a mixture of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide, N-hydroxysuccinimide and water, the mass fraction of the 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide in the solvent is 71%, the mass fraction of the N-hydroxysuccinimide in the solvent is 24%, and the mass fraction of the water in the solvent is 5%; the mass concentration of baicalin in the solution is 2wt%;
(5) Taking out the cornea bandage mirror treated in the step (4), cleaning with deionized water, then placing the cornea bandage mirror in a thiolated hyaluronic acid aqueous solution with the mass concentration of 2wt%, soaking the cornea bandage mirror for 0.5h at the temperature of 25 ℃ and then irradiating the cornea bandage mirror with ultraviolet light for 0.1h, and then cleaning the cornea bandage mirror with deionized water to obtain the cornea bandage mirror with the bionic layer structure.
Example 4
The preparation method of the cornea bandage mirror with the bionic layer structure comprises the following steps:
(1) Placing cornea bandage mirror into 2wt% tea polyphenol water solution with pH value of 8.5, soaking for 4 hr at 30deg.C;
(2) Taking out the cornea bandage mirror treated in the step (1), putting the cornea bandage mirror into a silver nitrate aqueous solution with the mass concentration of 2wt%, and soaking the cornea bandage mirror for 1min under the ultraviolet irradiation condition of 25 ℃ and 365 nm;
(3) Taking out the cornea bandage mirror treated in the step (2), cleaning with deionized water, then putting into an aqueous solution containing tea polyphenol and hexamethylenediamine, and soaking for 24 hours at 25 ℃; the mass concentration of tea polyphenol in the aqueous solution is 1wt%, and the mass concentration of hexamethylenediamine is 2.5wt%;
(4) Taking out the cornea bandage mirror treated in the step (3), washing with deionized water, then putting the cornea bandage mirror into a solution containing baicalin, soaking the cornea bandage mirror in the solution for 1h at the temperature of 30 ℃, wherein the solvent in the solution is a mixture of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide, N-hydroxysuccinimide and water, the mass fraction of the 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide in the solvent is 71%, the mass fraction of the N-hydroxysuccinimide in the solvent is 24%, and the mass fraction of the water in the solvent is 5%; the mass concentration of baicalin in the solution is 2wt%;
(5) Taking out the cornea bandage mirror treated in the step (4), cleaning with deionized water, then placing the cornea bandage mirror in a thiolated hyaluronic acid aqueous solution with the mass concentration of 2wt%, soaking the cornea bandage mirror for 0.5h at the temperature of 25 ℃ and then irradiating the cornea bandage mirror with ultraviolet light for 0.1h, and then cleaning the cornea bandage mirror with deionized water to obtain the cornea bandage mirror with the bionic layer structure.
Example 5
The preparation method of the cornea bandage mirror with the bionic layer structure comprises the following steps:
(1) Placing the cornea bandage mirror into 2wt% dopamine aqueous solution with pH value of 7.8, and soaking for 4h at 30deg.C;
(2) Taking out the cornea bandage mirror treated in the step (1), putting the cornea bandage mirror into a silver nitrate aqueous solution with the mass concentration of 2wt%, and soaking the cornea bandage mirror for 1min under the ultraviolet irradiation condition of 365nm at the temperature of 30 ℃;
(3) Taking out the cornea bandage mirror treated in the step (2), cleaning with deionized water, then putting into an aqueous solution containing dopamine and hexamethylenediamine, and soaking for 24 hours at 25 ℃; the mass concentration of dopamine in the aqueous solution is 2wt% and the mass concentration of hexamethylenediamine is 5wt%;
(4) Taking out the cornea bandage mirror treated in the step (3), washing with deionized water, then placing the cornea bandage mirror into a solution containing gallic acid, and soaking for 1h at the temperature of 30 ℃, wherein the solvent in the solution is a mixture of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide, N-hydroxysuccinimide and water, the mass fraction of the 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide in the solvent is 71%, the mass fraction of the N-hydroxysuccinimide in the solvent is 24%, and the mass fraction of the water in the solvent is 5%; the mass concentration of gallic acid in the solution is 1wt%;
(5) Taking out the cornea bandage mirror treated in the step (4), cleaning with deionized water, then placing the cornea bandage mirror in a thiolated hyaluronic acid aqueous solution with the mass concentration of 1wt%, soaking the cornea bandage mirror for 1h at the temperature of 25 ℃ and then irradiating the cornea bandage mirror with ultraviolet light for 0.1h, and then cleaning the cornea bandage mirror with deionized water to obtain the cornea bandage mirror with the bionic layer structure.
Example 6
The preparation method of the cornea bandage mirror with the bionic layer structure comprises the following steps:
(1) Placing cornea bandage mirror into tannic acid water solution with mass concentration of 2wt%, wherein pH value of water solution is 7.8, and soaking for 4h at 30deg.C;
(2) Taking out the cornea bandage mirror treated in the step (1), putting the cornea bandage mirror into a silver nitrate aqueous solution with the mass concentration of 2wt%, and soaking the cornea bandage mirror for 1min under the ultraviolet irradiation condition of 25 ℃ and 365 nm;
(3) Taking out the cornea bandage mirror treated in the step (2), cleaning with deionized water, then putting into an aqueous solution containing catechol and hexamethylenediamine, and soaking for 24 hours at 25 ℃; the mass concentration of dopamine in the aqueous solution is 1wt%, and the mass concentration of hexamethylenediamine is 2.5wt%;
(4) Taking out the cornea bandage mirror treated in the step (3), washing with deionized water, then putting the cornea bandage mirror into a solution containing baicalin, soaking the cornea bandage mirror in the solution for 1h at the temperature of 30 ℃, wherein the solvent in the solution is a mixture of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide, N-hydroxysuccinimide and water, the mass fraction of the 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide in the solvent is 71%, the mass fraction of the N-hydroxysuccinimide in the solvent is 24%, and the mass fraction of the water in the solvent is 5%; the mass concentration of baicalin in the solution is 1wt%;
(5) Taking out the cornea bandage mirror treated in the step (4), cleaning with deionized water, then placing the cornea bandage mirror in a thiolated hyaluronic acid aqueous solution with the mass concentration of 2wt%, soaking the cornea bandage mirror for 0.5h at the temperature of 25 ℃ and then irradiating the cornea bandage mirror with ultraviolet light for 0.1h, and then cleaning the cornea bandage mirror with deionized water to obtain the cornea bandage mirror with the bionic layer structure.
Example 7
The preparation method of the cornea bandage mirror with the bionic layer structure comprises the following steps:
(1) Placing the cornea bandage mirror into catechol water solution with the mass concentration of 2wt%, wherein the pH value of the water solution is 8.5, and soaking for 4 hours at the temperature of 30 ℃;
(2) Taking out the cornea bandage mirror treated in the step (1), putting the cornea bandage mirror into a silver nitrate aqueous solution with the mass concentration of 2wt%, and soaking the cornea bandage mirror for 1min under the ultraviolet irradiation condition of 25 ℃ and 365 nm;
(3) Taking out the cornea bandage mirror treated in the step (2), cleaning with deionized water, then putting into an aqueous solution containing catechol and hexamethylenediamine, and soaking for 24 hours at 25 ℃; the mass concentration of dopamine in the aqueous solution is 2wt% and the mass concentration of hexamethylenediamine is 5wt%;
(4) Taking out the cornea bandage mirror treated in the step (3), cleaning with deionized water, then placing the cornea bandage mirror into a solution containing gallic acid, and soaking the cornea bandage mirror in the solution for 0.5h at the temperature of 40 ℃, wherein the solvent in the solution is a mixture of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide, N-hydroxysuccinimide and water, the mass fraction of the 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide in the solvent is 71%, the mass fraction of the N-hydroxysuccinimide in the solvent is 24%, and the mass fraction of the water in the solvent is 5%; the mass concentration of gallic acid in the solution is 2wt%;
(5) Taking out the cornea bandage mirror treated in the step (4), cleaning with deionized water, then placing the cornea bandage mirror in a thiolated hyaluronic acid aqueous solution with the mass concentration of 2wt%, soaking the cornea bandage mirror for 0.5h at the temperature of 25 ℃ and then irradiating the cornea bandage mirror with ultraviolet light for 0.1h, and then cleaning the cornea bandage mirror with deionized water to obtain the cornea bandage mirror with the bionic layer structure.
Example 8
The preparation method of the cornea bandage mirror with the bionic layer structure comprises the following steps:
(1) Placing the cornea bandage mirror into a 4wt% dopamine aqueous solution, wherein the pH value of the aqueous solution is 8.5, and soaking for 2 hours at 30 ℃;
(2) Taking out the cornea bandage mirror treated in the step (1), putting the cornea bandage mirror into a silver nitrate aqueous solution with the mass concentration of 4wt%, and soaking the cornea bandage mirror for 1min under the ultraviolet irradiation condition of 25 ℃ and 365 nm;
(3) Taking out the cornea bandage mirror treated in the step (2), cleaning with deionized water, then putting into an aqueous solution containing dopamine and polyethylene polyamine, and soaking for 24 hours at 25 ℃; the mass concentration of dopamine in the aqueous solution is 1wt%, and the mass concentration of hexamethylenediamine is 2.5wt%;
(4) Taking out the cornea bandage mirror treated in the step (3), washing with deionized water, then placing the cornea bandage mirror into a solution containing gallic acid, and soaking for 1h at the temperature of 30 ℃, wherein the solvent in the solution is a mixture of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide, N-hydroxysuccinimide and water, the mass fraction of the 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide in the solvent is 71%, the mass fraction of the N-hydroxysuccinimide in the solvent is 24%, and the mass fraction of the water in the solvent is 5%; the mass concentration of gallic acid in the solution is 4wt%;
(5) Taking out the cornea bandage mirror treated in the step (4), cleaning with deionized water, then placing the cornea bandage mirror in a thiolated hyaluronic acid aqueous solution with the mass concentration of 2wt%, soaking the cornea bandage mirror for 0.5h at the temperature of 25 ℃ and then irradiating the cornea bandage mirror with ultraviolet light for 0.1h, and then cleaning the cornea bandage mirror with deionized water to obtain the cornea bandage mirror with the bionic layer structure.
Experimental example
FIG. 1 is a schematic view of the preparation process of a cornea bandage mirror with a bionic layer structure in example 1.
Taking the cornea bandage mirror before and after modification in the example 1 as an example, the performance change before and after modification is detected, and the specific detection process is as follows:
1. water contact angle test
The change in hydrophilicity of each sample before and after surface modification was examined using a droplet shape analysis system (DSA 100, kruss, germany), and the specific examination results are shown in fig. 2.
As can be seen from fig. 2, the water contact angle of the surface of the modified cornea bandage mirror is 33 °, and the water contact angle of the cornea bandage mirror before modification is 92 °, and the water contact angle of the cornea bandage mirror before modification is far greater than that of the cornea bandage mirror after modification, which proves that the cornea bandage mirror after modification has better hydrophilicity and wettability. The modified cornea bandage mirror can improve the comfort level of eyes in the use process, and is convenient for eyes to recover.
2. Silver ion release experiment
(1) Soaking the modified cornea bandage mirror in 4mL of PBS solution at 37 ℃, collecting the soaked PBS solution at 1, 3, 5, 7, 10, 15 and 30 days respectively, and adding 4mL of new PBS solution for continuous soaking;
(2) And (3) detecting (1) the silver particle content in the collected PBS solution by adopting an atomic absorption spectrum (ASS, japen-Hitachi-Z-2300), and calculating the total silver particle content in the coating. The specific results are shown in FIG. 3.
As can be seen from fig. 3, as the soaking time is prolonged, the content of silver ions in the PBS solution gradually increases, which indicates that the modified coating can release silver ions for a long time, and the silver ions can be sterilized in a broad spectrum, thereby realizing a long-term antibacterial effect.
3. Antioxidant experiment
(1) Taking an unmodified cornea bandage mirror as a control group, and placing the unmodified cornea bandage mirror and cornea bandage mirror samples at different modification stages in a hydrogen peroxide aqueous solution with the concentration of 0.01M;
(2) The contact angles of water on the surface of the cornea bandage mirror before soaking, at 6h, 12h and 24h are respectively tested. The hydrophilicity change is used to characterize the oxidation resistance of all samples before and after modification. The specific results are shown in FIG. 4.
As can be seen from fig. 4, the surface structure of the modified sample is destroyed by oxidizing the surface of the modified sample with hydrogen peroxide, and the hydrophilicity is reduced, so that the water contact angle is changed. Baicalin has a large amount of polyphenols, has a certain reducibility, and can resist oxidation. Before baicalin grafting modification, the water contact angle increases with the increase of the hydrogen peroxide soaking time. However, after baicalin is grafted, the change of the water contact angle is obviously reduced, which proves that the modified coating has good oxidation resistance.
4. Bacterial adhesion experiments
(1) The cornea bandage mirror before and after modification is placed at a concentration of 1X 10 6 Incubating CFU/ml in PBS solution of pseudomonas aeruginosa or staphylococcus aureus for 1h at 37 ℃;
(2) Removing the treated keratoscope of (1) from the PBS solution and rinsing 5 times with PBS solution;
(3) Treating the cornea bandage mirror treated in the step (2) with 2.5% glutaraldehyde solution at 4 ℃ for 24 hours;
(4) Taking out the cornea bandage mirror treated in the step (3), cleaning with normal saline, and then dyeing for 15min by using rhodamine normal saline solution;
(5) Taking out the cornea bandage mirror treated in the step (4), washing 3 times by using normal saline, and drying and using a fluorescence microscope to adhere bacteria on the surface of the cornea bandage mirror. The specific results are shown in FIGS. 5-6.
As can be seen from FIG. 5, after the corneal bandage mirror before modification is treated with Pseudomonas aeruginosa and Staphylococcus aureus, the surface of the corneal bandage mirror contains a large amount of Pseudomonas aeruginosa or Staphylococcus aureus.
As can be seen from fig. 6, after the modified cornea bandage mirror is treated by pseudomonas aeruginosa and staphylococcus aureus, the number of the pseudomonas aeruginosa and the staphylococcus aureus on the surface of the cornea bandage mirror is obviously reduced, which proves that silver ions added in the cornea bandage mirror in the modification process have stronger bactericidal effect, can effectively kill the pseudomonas aeruginosa or the staphylococcus aureus, and reduce the pollution to eyes of patients.
5. Inflammatory cell culture experiments
(1) Cutting the cornea bandage mirrors before and after modification into wafers with diameters of 8mm, and placing the wafers in a 48-hole plate;
(2) Adding 3X 10 to the well plate in which the sample was placed in (1) 4 Mouse macrophage cell/mL, and placing in a cell incubator for culturing for 1 and 3 days;
(3) Taking out the cornea bandage mirror after incubation in the step (2), lightly flushing for 3 times by using normal saline, sucking out, and then adding glutaraldehyde normal saline solution with the volume concentration of 2.5% for fixation for 24 hours;
(4) The cornea bandage mirror treated in the step (3) is taken out and stained with rhodamine physiological saline solution for 15min.
(5) Taking out the cornea bandage mirror treated in the step (4), washing 3 times by using normal saline, and drying and using a fluorescence microscope to adhere macrophages on the cornea bandage mirror surface. The specific results are shown in FIGS. 7-8.
As can be seen from fig. 7, the surface of the cornea bandage mirror before modification contains a large number of macrophages, which proves that the surface of the cornea bandage mirror generates inflammation;
as can be seen from fig. 8, the macrophages on the surface of the modified cornea bandage mirror are obviously reduced, and the modified cornea bandage mirror has a certain anti-inflammatory effect.
6. Anti-hyaluronidase assay
Omitting the operation in step (4) on the basis of the production method in example 1 to produce a keratome, and conducting an experiment using the keratome and the keratome produced in example 1 as samples; the method comprises the following steps:
(1) 1mL of hyaluronidase PBS solution with the concentration of 100mg/L is added to the surface of the sample, the cornea bandage mirror sample is collected after incubation for 3 h at 37 ℃, and the cornea bandage mirror sample is rinsed by deionized water;
(2) Cutting the cornea bandage mirror collected in the step (1) into wafers with diameters of 8mm, and placing the wafers in a 48-well plate;
(3) Adding 3X 10 to the well plate in which the sample was placed in (2) 4 Mouse macrophages at each mL and placed in a cell incubator for 1 day;
(4) Taking out the cornea bandage mirror after incubation in the step (3), lightly flushing for 3 times by using normal saline, sucking out, and then adding glutaraldehyde normal saline solution with the volume concentration of 2.5% for fixation for 24 hours;
(5) The cornea bandage mirror treated in the step (4) is taken out and stained with rhodamine physiological saline solution for 15min.
(6) Taking out the cornea bandage mirror treated in the step (5), washing the cornea bandage mirror with normal saline for 3 times, and detecting adhesion of macrophages on the surface of the cornea bandage mirror by using a fluorescence microscope after the cornea bandage mirror is dried. The specific results are shown in FIG. 9.
As can be seen from fig. 9, the anti-inflammatory properties of the hyaluronic acid layer without baicalin grafted thereto were significantly reduced after hyaluronidase action, because part of the hyaluronic acid was decomposed and the insulation effect was reduced. The difference between the front and the back of the hyaluronic acid layer grafted with the baicalin is not great, because the baicalin has the function of inhibiting the enzyme activity, and the grafting of the baicalin can reduce the decomposition of the hyaluronic acid by the hyaluronidase.
7. Corneal epithelial cell culture experiments
(1) Add 3X 10 to 24 well plate 4 individual/mL human corneal epithelial cells and placed in a cell incubator for 1 day;
(2) Placing the cornea bandage mirrors before and after modification in a 24-hole plate in which the human cornea epithelial cells are cultured in the step (1), and placing the cornea bandage mirrors in a cell incubator for culturing for 2 days;
(3) Taking out the cornea bandage mirror after incubation in the step (2), lightly flushing a 24-pore plate with physiological saline for 3 times and sucking out, and then adding glutaraldehyde physiological saline solution with the volume concentration of 2.5% into the 24-pore plate for fixation for 24 hours;
(4) Staining the corneal epithelial cells in the well plate with rhodamine physiological saline solution for 15min;
(5) The 24-well plate treated in the above step (4) was washed 3 times with physiological saline, and after drying, adhesion of corneal epithelial cells inside the well was observed by using a fluorescence microscope. The specific results are shown in FIG. 10.
As can be seen from fig. 10, the number of corneal epithelial cells on the surface of the modified sample is increased, which indicates that the constructed bionic glycocalyx structure has good biocompatibility and can effectively promote cornea repair.
The foregoing description of the preferred embodiments of the invention is not intended to limit the invention to the precise form disclosed, and any such modifications, equivalents, and alternatives falling within the spirit and scope of the invention are intended to be included within the scope of the invention.
Claims (10)
1. The preparation method of the cornea bandage mirror with the bionic layer structure is characterized by comprising the following steps of:
immersing cornea bandage mirror in water solution A containing polyphenol compound, water solution B containing silver ion, water solution C containing polyphenol compound and polyamine group compound, water solution D containing polyphenol compound and water solution E containing sulfhydryl hyaluronic acid in turn, and finally washing with deionized water to obtain the cornea bandage mirror;
the polyphenol compound in the aqueous solution A and the aqueous solution C comprises at least one of dopamine, tea polyphenol, tannic acid, anthocyanin, catechol, gallic acid and epicatechin; the polyphenol compound in the solution D is at least one of gallic acid and baicalin;
wherein, the cornea bandage mirror is soaked in the solution B and the solution E and simultaneously irradiated by ultraviolet light.
2. The method for producing a cornea bandage mirror having a bionic layer structure according to claim 1, wherein the mass concentration of the polyphenol compound in the aqueous solution a is 0.5 to 4%.
3. The method for preparing a cornea bandage mirror with a bionic layer structure according to claim 2, wherein the pH value of the aqueous solution a is 7.0-9.0, the soaking temperature of the cornea bandage mirror in the aqueous solution a is 20-40 ℃ and the soaking time is 1-8h.
4. The method for preparing a cornea bandage mirror with a bionic layer structure according to claim 1, wherein silver ions are provided by silver nitrate, the mass concentration of the silver ions in the aqueous solution B is 0.5-4%, the soaking temperature of the cornea bandage mirror in the aqueous solution B is 20-40 ℃, and the soaking time is 1-30min.
5. The method for producing a cornea bandage mirror having a bionic layer structure according to claim 1, wherein the polyamine group compound in the aqueous solution C comprises at least one of hexamethylenediamine and polyethylene polyamine; the mass concentration of the polyphenol compound in the aqueous solution C is 0.5-2%, and the mass concentration of the polyamine group compound in the aqueous solution C is 0.5-5%.
6. The method for producing a cornea bandage mirror with a bionic layer structure according to claim 5, wherein the immersing temperature of the cornea bandage mirror in the aqueous solution C is 25-40 ℃ and the immersing time is 12-48h.
7. The method for preparing a cornea bandage mirror with a bionic layer structure according to claim 1, wherein the solvent in the solution D is a mixture of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide, N-hydroxysuccinimide and water; wherein the mass fraction of the 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide in the solvent is 70-73%, the mass fraction of the N-hydroxysuccinimide in the solvent is 22-25%, and the mass fraction of the water in the solvent is 2-8%;
the mass concentration of the polyphenol compound in the solution D is 1-10%.
8. The method for preparing a cornea bandage mirror with a bionic layer structure according to claim 1 or 7, wherein the soaking temperature of the cornea bandage mirror in the solution D is 25-40 ℃ and the soaking time is 0.5-2h.
9. The method for preparing the cornea bandage mirror with the bionic layer structure according to claim 1, wherein the mass concentration of the sulfhydryl hyaluronic acid in the aqueous solution E is 1-5%, the soaking temperature of the cornea bandage mirror in the aqueous solution E is 25-40 ℃, and the soaking time is 0.1-2h.
10. A keratology with biomimetic layered structure, characterized in that it is produced by the method of any one of claims 1-9.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311151277.XA CN116870263B (en) | 2023-09-07 | 2023-09-07 | Cornea bandage mirror with bionic layer structure and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311151277.XA CN116870263B (en) | 2023-09-07 | 2023-09-07 | Cornea bandage mirror with bionic layer structure and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116870263A CN116870263A (en) | 2023-10-13 |
| CN116870263B true CN116870263B (en) | 2023-11-21 |
Family
ID=88272218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311151277.XA Active CN116870263B (en) | 2023-09-07 | 2023-09-07 | Cornea bandage mirror with bionic layer structure and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116870263B (en) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107106627A (en) * | 2014-10-10 | 2017-08-29 | 彼得·F·卡罗 | Anti-oxidant eyedrops |
| CN108498878A (en) * | 2018-07-05 | 2018-09-07 | 四川大学 | One kind having the bio-medical hydrogel coating and preparation method thereof of " sandwich " interlayer structure |
| CN109796616A (en) * | 2019-01-11 | 2019-05-24 | 西北大学 | The method and application of a kind of Biomimetic Polymers and the double Biomimetic Polymers coatings of production durability |
| WO2019190402A1 (en) * | 2018-03-28 | 2019-10-03 | Singapore Health Services Pte Ltd | Biocompatible ophthalmic device |
| TWI712403B (en) * | 2019-08-26 | 2020-12-11 | 長庚大學 | Water glue dressing |
| CN213076201U (en) * | 2020-05-18 | 2021-04-30 | 浙江大学 | Porous cornea contact lens loaded with tacrolimus liposome |
| CN112778772A (en) * | 2020-12-31 | 2021-05-11 | 中山大学附属第一医院 | Antibacterial composite hydrogel and preparation method and application thereof |
| CN115428807A (en) * | 2021-06-02 | 2022-12-06 | 西南大学 | Ti-SSC-Ag sterilization material and preparation method and application thereof |
| CN116077727A (en) * | 2023-01-13 | 2023-05-09 | 浙江大学 | Conductive fiber bundle composite hydrogel material with three-level nested structure and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2012029160A1 (en) * | 2010-09-02 | 2013-10-28 | 株式会社メニコン | Stabilized polyphenol solution and method for stabilizing polyphenol solution |
| CN113975458B (en) * | 2021-11-19 | 2022-07-26 | 浙江大学 | Nano-silver/double-modified chitosan antibacterial hydrogel dressing for indicating wound infection condition through color-changing effect and preparation method thereof |
-
2023
- 2023-09-07 CN CN202311151277.XA patent/CN116870263B/en active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107106627A (en) * | 2014-10-10 | 2017-08-29 | 彼得·F·卡罗 | Anti-oxidant eyedrops |
| WO2019190402A1 (en) * | 2018-03-28 | 2019-10-03 | Singapore Health Services Pte Ltd | Biocompatible ophthalmic device |
| CN108498878A (en) * | 2018-07-05 | 2018-09-07 | 四川大学 | One kind having the bio-medical hydrogel coating and preparation method thereof of " sandwich " interlayer structure |
| CN109796616A (en) * | 2019-01-11 | 2019-05-24 | 西北大学 | The method and application of a kind of Biomimetic Polymers and the double Biomimetic Polymers coatings of production durability |
| TWI712403B (en) * | 2019-08-26 | 2020-12-11 | 長庚大學 | Water glue dressing |
| CN213076201U (en) * | 2020-05-18 | 2021-04-30 | 浙江大学 | Porous cornea contact lens loaded with tacrolimus liposome |
| CN112778772A (en) * | 2020-12-31 | 2021-05-11 | 中山大学附属第一医院 | Antibacterial composite hydrogel and preparation method and application thereof |
| CN115428807A (en) * | 2021-06-02 | 2022-12-06 | 西南大学 | Ti-SSC-Ag sterilization material and preparation method and application thereof |
| CN116077727A (en) * | 2023-01-13 | 2023-05-09 | 浙江大学 | Conductive fiber bundle composite hydrogel material with three-level nested structure and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| A Mussel-Inspired Facile Method to Prepare Multilayer-AgNP-Loaded Contact Lens for Early Treatment of Bacterial and Fungal Keratitis;Liu Xiaoqi;ACS BIOMATERIALS SCIENCE & ENGINEERING;第4 卷(第5期);1568-1579 * |
| Nano polydopamine corsslinked thiol-functionalized hyaluronic acid hydrogel for angiogenic drug delivery;Yegappan Ramanathan;Colloids and surfaces B-biointerfaces;第177卷;41-49 * |
| 新型医用涂层用于负载生物活性功能分子的研究;江璟;中国博士学位论文全文数据库;B020-1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116870263A (en) | 2023-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ozdal et al. | Recent advances in nanoparticles as antibacterial agent | |
| Ma et al. | Commercial soft contact lenses engineered with zwitterionic silver nanoparticles for effectively treating microbial keratitis | |
| Raho et al. | Photo-assisted green synthesis of silver doped silk fibroin/carboxymethyl cellulose nanocomposite hydrogels for biomedical applications | |
| Wu et al. | Synthetic β-sheet forming peptide amphiphiles for treatment of fungal keratitis | |
| Kharaghani et al. | Development of antibacterial contact lenses containing metallic nanoparticles | |
| JP2001508041A (en) | Contact killing / non-leaching antibacterial material | |
| Gao et al. | Biomimetic biodegradable Ag@ Au nanoparticle-embedded ureteral stent with a constantly renewable contact-killing antimicrobial surface and antibiofilm and extraction-free properties | |
| Feng et al. | Rapid inactivation of multidrug-resistant bacteria and enhancement of osteoinduction via titania nanotubes grafted with polyguanidines | |
| CN113842508B (en) | Antibacterial bionic coating and preparation method and application thereof | |
| US20160235881A1 (en) | Non-adherent hydrogel coating for wound dressings and methods for making the same | |
| KR100878053B1 (en) | Antibacterial contact lens compring naringin and process for preparing the same | |
| Wang et al. | “Kill-release” antibacterial polysaccharides multilayer coating based therapeutic contact lens for effective bacterial keratitis treatment | |
| CN116870263B (en) | Cornea bandage mirror with bionic layer structure and preparation method thereof | |
| US20240041047A1 (en) | Enhanced antimicrobial efficacy (synergy) of silver and copper compounds and medical use of their combinations | |
| Tabary et al. | Functionalization of PVDF membranes with carbohydrate derivates for the controlled delivery of chlorhexidin | |
| Yarmamedov et al. | Study of the pharmacological impact of polymeric membranes with antibacterial effect in traumatic lesions of cornea | |
| Shimmura et al. | Acidic electrolysed water in the disinfection of the ocular surface | |
| Zhang et al. | Bionic antibacterial modification of IOL through SI-RAFT polymerization of P (TOEAC-co-MPC) brushes to prevent PCO and endophthalmitis | |
| CN114668778B (en) | Microneedle for promoting wound healing | |
| CN116139067B (en) | Method for forming gel by zinc hyaluronate and eye drop gel containing zinc hyaluronate and preparation thereof | |
| CN113069556B (en) | Oxidized alginic acid fiber membrane of cladinostat and preparation method thereof | |
| CN105126149B (en) | A kind of medical recombination chitosan application | |
| CN113207905A (en) | Contact lens care composition and preparation method thereof | |
| Luo et al. | Multifunctional Baicalin-Modified Contact Lens for Preventing Infection, Regulating the Ocular Surface Microenvironment and Promoting Corneal Repair | |
| US11992674B2 (en) | Graphene oxide cochlear implant electrode and manufacturing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |